Kelun Pharma: Revenue growth is expected to be 19%-22% by 2026.

MetaMuskRat · 2026-04-04T02:07:13+00:00

People's Financial News, April 4th — On April 3rd, at the earnings presentation, Kelly Engineering stated that the company expects a revenue growth of 19%-22% by 2026. Looking at the business segments for 2026: The small molecule business is still in the adjustment phase, but the commercialization projects are performing well, and overall, the company is maintaining a steady trend. Emerging businesses are expected to continue high growth, and the performance of the two large molecule business segments is anticipated to be more prominent.

MetaMuskRat

2026-04-04 02:07:13

People’s Finance and News, April 4: On April 3, Kelaiying said at an earnings briefing that the company expects 2026 operating revenue growth of 19%-22%. In its outlook for 2026 by business segment: the small-molecule business is still in an adjustment phase, and its commercialized projects are performing impressively, so the overall business can maintain a steady and robust trend. The emerging businesses are expected to continue sustaining a high-growth momentum, and the two large-molecule business segments are expected to perform even more strongly.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.